ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

DDDD 4d Pharma Plc

16.36
0.00 (0.00%)
01 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
4d Pharma Plc LSE:DDDD London Ordinary Share GB00BJL5BR07 ORD 0.25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 16.36 0.00 01:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

4d Pharma PLC Total Voting Rights (5917N)

01/02/2021 2:10pm

UK Regulatory


4d Pharma (LSE:DDDD)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more 4d Pharma Charts.

TIDMDDDD

RNS Number : 5917N

4d Pharma PLC

01 February 2021

4D Pharma

Total Voting RIghts

Leeds, UK, February 1, 2021 - 4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announces that following the recent exercise of 30,620 warrants to subscribe for ordinary shares, the Company's issued share capital will comprise 131,498,555 Ordinary Shares. The total number of voting rights in the Company will be 131,498,555.

This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Disclosure Guidance and Transparency Rules of the Financial Conduct Authority.

Contact Information:

4D pharma

Duncan Peyton, Chief Executive Officer +44 (0)113 895 0130

Investor Relations: ir@4dpharmaplc.com

N+1 Singer - Nominated Adviser and Joint Broker +44 (0)20 7496 3000

Philip Davies / Iqra Amin / James Fischer (Corporate Finance)

Tom Salvesen (Corporate Broking)

Bryan Garnier & Co. Limited - Joint Broker +44 (0)20 7332 2500

Dominic Wilson / Phil Walker

Stern Investor Relations, Inc. +1-212-362-1200

Julie Seidel Julie.seidel@sternir.com

Image Box Communications +44 (0)20 8943 4685

Neil Hunter / Michelle Boxall

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

TVRDKDBKQBKDCBK

(END) Dow Jones Newswires

February 01, 2021 09:10 ET (14:10 GMT)

1 Year 4d Pharma Chart

1 Year 4d Pharma Chart

1 Month 4d Pharma Chart

1 Month 4d Pharma Chart

Your Recent History

Delayed Upgrade Clock